Egenesis Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 154

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 34

Egenesis General Information

Description

Developer of human-compatible engineered organs and cells designed to address the global shortage of transplantable organs. The company offers a genome-engineering platform that inactivates porcine retroviruses, inserts human genes, and edits multiple immune-rejection pathways to transform solid organ and therapeutic cell transplantation for the treatment of life-threatening diseases, enabling patients with organ failure to access transplantable tissues and organs with improved compatibility and safety.

Contact Information

Website
www.egenesisbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 101 Cambridgepark Drive
  • Suite 200
  • Cambridge, MA 02140
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 101 Cambridgepark Drive
  • Suite 200
  • Cambridge, MA 02140
  • United States
+1 (617)

Egenesis Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Egenesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 29-Sep-2026 Completed Clinical Trials - General
8. Secondary Transaction - Private 01-Jul-2026 Completed Clinical Trials - General
7. Later Stage VC (Series D) 04-Sep-2024 Completed Clinical Trials - General
6. Later Stage VC (Series C) 01-Mar-2021 Completed Clinical Trials - General
5. Early Stage VC (Series B) 01-Nov-2019 Completed Clinical Trials - General
4. Early Stage VC (Series A) 13-Mar-2017 Completed Clinical Trials - General
3. Accelerator/Incubator Completed Startup
2. Accelerator/Incubator Completed Startup
1. University Spin-Out 01-Jan-2015 Completed Startup
To view Egenesis’s complete valuation and funding history, request access »

Egenesis Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series D1
Series D
Series C1
Series B1 55,111,122 $0.000020 $0.14 $1.81 $1.81 1x $1.81 3.29%
Series A1 27,375,893 $0.000020 $0.11 $1.43 $1.43 1x $1.43 1.63%
To view Egenesis’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Egenesis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of human-compatible engineered organs and cells designed to address the global shortage of transplantable orga
Drug Discovery
Cambridge, MA
154 As of 2026

Pittsburgh, PA
 

Seattle, WA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Egenesis Competitors (37)

One of Egenesis’s 37 competitors is LyGenesis, a Venture Capital-Backed company based in Pittsburgh, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
LyGenesis Venture Capital-Backed Pittsburgh, PA
Immusoft Venture Capital-Backed Seattle, WA
Voyager Therapeutics Formerly VC-backed Lexington, MA
Ossium Health Venture Capital-Backed San Francisco, CA
Arbor Biotechnologies Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 37 competitors. Get the full list »

Egenesis Patents

  • 54

    Total Documents Applications and Grants

  • Total Patents Families

  • 23

    Granted

  • 22

    Pending

  • Expiring in next 12 mo

Egenesis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202308468-D0 Cells, tissues, organs and animals having one or more modified genes for enhanced xenograft survival and tolerance Active 13-Nov-2020
GB-2618225-A Cells, tissues, organs and animals having one or more modified genes for enhanced xenograft survival and tolerance Active 13-Nov-2020
GB-2618225-B Cells, tissues, organs and animals having one or more modified genes for enhanced xenograft survival and tolerance Active 13-Nov-2020
AU-2021380845-A1 Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance Pending 13-Nov-2020
AU-2021380845-A9 Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance Pending 13-Nov-2020 C12N15/85
To view Egenesis’s complete patent history, request access »

Egenesis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Egenesis Investors (34)

Investor Name Investor Type Holding Investor Since Participating Rounds
15th Rock Venture Capital Minority
Hokkaido University University Minority
b2venture Venture Capital Minority
DaVita Corporation Minority
DaVita Venture Group Corporate Venture Capital Minority
You’re viewing 5 of 34 investors. Get the full list »

Egenesis Acquisitions (1)

Egenesis’s most recent deal was a Merger/Acquisition with ICBiotec. The deal was made on 20-May-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ICBiotec 20-May-2020 Merger/Acquisition Drug Discovery
To view Egenesis’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Egenesis FAQs

  • When was Egenesis founded?

    Egenesis was founded in 2015.

  • Where is Egenesis headquartered?

    Egenesis is headquartered in Cambridge, MA.

  • What is the size of Egenesis?

    Egenesis has 154 total employees.

  • What industry is Egenesis in?

    Egenesis’s primary industry is Drug Discovery.

  • Is Egenesis a private or public company?

    Egenesis is a Private company.

  • What is Egenesis’s current revenue?

    The current revenue for Egenesis is .

  • How much funding has Egenesis raised over time?

    Egenesis has raised $454M.

  • Who are Egenesis’s investors?

    15th Rock, Hokkaido University, b2venture, DaVita, and DaVita Venture Group are 5 of 34 investors who have invested in Egenesis.

  • Who are Egenesis’s competitors?

    LyGenesis, Immusoft, Voyager Therapeutics, Ossium Health, and Arbor Biotechnologies are some of the 37 competitors of Egenesis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process